| Habil Khorakiwala, chairman of the company, said it was looking at an export turnover of Rs 100 crore in 2005 for recombinant drugs. |
| "Over the next few years, we expect more than 75 per cent of our output to be exported worldwide," he pointed out. |
| The fifth largest pharmaceutical company of the country has come up with a dedicated facility for bio-pharma last month in Aurangabad. It has invested Rs 200 crore for the three lakh square feet biotechnology park. |
| Biotechnology is the thrust area for Wockhardt's research and development. |
| "This science is viewed by global experts as the technology of the future, and Wockhardt has a strong commitment to this field," he noted. |
| Wockhardt's in-house biotechnology team has already succeeded in developing Biovac-B (hepatitis-B) vaccine, Wepox (erythropoietin) and Wosulin (rDNA human insulin). Several other products are under development including interferon alpha 2B and other anti-cancer drugs. |
| Wosulin, India's first recombinant human insulin drug, was developed in August 2003, making India the first Asian country to develop, manufacture and market the product. With this, it became the fourth company in the world to manufacture and market recombinant human insulin. |
| It had achieved a breakthrough in development of Glargine, a new generation advance on insulin. The phase III clinical trials will be initiated soon with Glargine and |
| it is expected to be introduced in India in the next 18 months. |
| The capacities and capabilities at the new facility is aimed at meeting 10 to 15 per cent of the global demands of these medicines. The current sale of bio-pharmaceuticals worldwide is $40 billion, and by 2010, it is likely to cross $100 billion mark. |
| Wockhardt's bio-pharma products have been registered in 10 countries in South-East Asia, Central Asia, South Africa and more countries would be added to the list. |
Top Section
Explore Business Standard